Major changes in sickle cell disease.
Clinical, molecular, and genetic advances have revealed new pathophysiologic insights and treatments for the growing number of recognized hematologic and nonhematologic abnormalities in sickle cell disease. Treatment targets of cellular dehydration, sickle hemoglobin concentrations, endothelial dysfunction, and abnormal coagulation regulation have been validated as potential therapy. New uses for transfusion therapy hold the promise of decreased major symptoms of acute chest syndrome, stroke, and severe pain crises, but at the expense of increased risk for transfusion reactions, infections, and iron overload. Accumulated experience with autologous, chimeric, and stem cell bone marrow transplantation holds promise for a small percentage of patients with disease. Patient selection, suitable donors, and early mortality are still limiting factors. Genetic manipulation, which offers hope for ameliorating the disease in a larger percentage of patients, is progressing slowly. Combination and staged therapies will be developed and matched to the severity and progression of the patient's disease. Strategies for prevention of major organ damage to the brain, heart, lungs, and kidneys will be prospectively evaluated and refined.
Hagar
R W
RW
Stanford University, Calif., USA.
Vichinsky
E P
EP
D001803:Blood Transfusion; D016026:Bone Marrow Transplantation; D003676:Deferoxamine / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005319:Fetal Hemoglobin / Q000378:metabolism; D015316:Genetic Therapy; D006450:Hemoglobin SC Disease / Q000235:genetics / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007093:Imidazoles / Q000627:therapeutic use; D008017:Life Expectancy; D012307:Risk Factors
D004791:Enzyme Inhibitors; D007093:Imidazoles; C029899:imidazole; D005319:Fetal Hemoglobin; D003676:Deferoxamine; D006918:Hydroxyurea